Wave is expecting feedback from US regulators on a path forward for WVE-006 as a potential alpha-1 antitrypsin deficiency therapy in mid-2026.

PM EST TAMPA, Fla. and LONDON, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology ...

WVE-006 is a first-in-class RNA editing therapeutic candidate designed to correct the root cause of disease for the 200,000 individuals in the ...

The RNA analysis market is poised for significant growth due to rising demand in precision medicine, advancements in NGS technologies, and expanding use of RNA biomarkers in diagnostics and drug ...

In 2023, Krainer published a paper in which he showed SRSF1’s involvement in PDAC. The most common form of pancreatic cancer, PDAC is also the most life- threatening. By increasing SRSF1 into a system ...

A new AI model by Google DeepMind can decipher DNA and predict mutations, opening new doors for disease research. View on ...

AlphaGenome is a DNA sequence model that advances regulatory variant-effect prediction to understand genome function.

Skyhawk Therapeutics announces interim results in patients from phase 1 clinical trial as a treatment for Huntington’s disease: Waltham, Massachusetts Thursday, January 29, 2026 ...

Antal and Yeo, who also are members of UCSD’s Moores Cancer Center, say the key to targeting triple-negative breast cancer, or TNBC, is managing a protein called poly (U)-binding splicing factor 60, ...

Skyhawk Therapeutics shared results for SKY-0515, a drug designed to lower huntingtin. The drug appeared generally safe, with 60% reduction of huntingtin in blood at the highest dose tested. This data ...

Inc., a clinical-stage biotechnology company developing novel small molecule therapies to modulate critical RNA ...

Company expands its ADC pipeline and patent estate for novel, differentiated ADCs New pipeline candidate AKTX-102 leverages ...